PCN262 PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL
Abstract
Authors
D. Patrick L. Matza Y. Kim J. Garcia C. Dehner K.C. Chung